PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer

Munkácsy, Gyöngyi; Abdul-Ghani, Rula; Mihály, Zsuzsanna; Tegze, Bálint; Tchernitsa, Oleg I.; Surowiak, Paweł; Schäfer, Reinhold; Győrffy, Balázs

doi:10.1038/sj.bjc.6605478

Cited by 41 publications

(28 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LHX2 is a TF involved in the differentiation of developing lymphoid and neural cell precursors and is a putative oncogene for pancreatic tumors (Zhou et al, 2014). PSMB7 is a proteasome subunit that was identified as a biomarker for breast and colon cancers (Munkácsy et al , 2010). As shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

cis -Regulatory Circuits Regulating NEK6 Kinase Overexpression in Transformed B Cells Are Super-Enhancer Independent

et al. 2017

View full text Add to dashboard Cite

SUMMARY Alterations in distal regulatory elements that control gene expression underlie many diseases, including cancer. Epigenomic analyses of normal and diseased cells have produced correlative predictions for connections between dysregulated enhancers and target genes involved in pathogenesis. However, with few exceptions, these predicted cis-regulatory circuits remain untested. Here, we dissect cis-regulatory circuits that lead to overexpression of NEK6, a mitosis-associated kinase, in human B cell lymphoma. We find that only a minor subset of predicted enhancers is required for NEK6 expression. Indeed, an annotated super-enhancer is dispensable for NEK6 overexpression and for maintaining the architecture of a B cell-specific regulatory hub. A CTCF cluster serves as a chromatin and architectural boundary to block communication of the NEK6 regulatory hub with neighboring genes. Our findings emphasize that validation of predicted cis-regulatory circuits and super-enhancers is needed to prioritize transcriptional control elements as therapeutic targets.

show abstract

Section: Resultsmentioning

confidence: 99%

cis -Regulatory Circuits Regulating NEK6 Kinase Overexpression in Transformed B Cells Are Super-Enhancer Independent

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Smith et al (2007) reported that the over-expression of the PSMB1 proteasomal subunit is associated with resistance to cisplatin in cancer cell lines [44]. Furthermore, PSMB7 has been proved to be associated with anthracycline-resistance in breast cancer [45]. Overexpression of the POH1 subunit confers resistance to vinblastine, cisplatin, doxorubicin and paclitaxel in mammalian cells [43].…”

Section: Discussionmentioning

confidence: 99%

Identification of Proteasome Subunit Beta Type 6 (PSMB6) Associated with Deltamethrin Resistance in Mosquitoes by Proteomic and Bioassay Analyses

Sun

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

Deltamethrin (DM) insecticides are currently being promoted worldwide for mosquito control, because of the high efficacy, low mammalian toxicity and less environmental impact. Widespread and improper use of insecticides induced resistance, which has become a major obstacle for the insect-borne disease management. Resistance development is a complex and dynamic process involving many genes. To better understand the possible molecular mechanisms involved in DM resistance, a proteomic approach was employed for screening of differentially expressed proteins in DM-susceptible and -resistant mosquito cells. Twenty-seven differentially expressed proteins were identified by two-dimensional electrophoresis (2-DE) and mass spectrometry (MS). Four members of the ubiquitin-proteasome system were significantly elevated in DM-resistant cells, suggesting that the ubiquitin-proteasome pathway may play an important role in DM resistance. Proteasome subunit beta type 6 (PSMB6) is a member of 20S proteasomal subunit family, which forms the proteolytic core of 26S proteasome. We used pharmaceutical inhibitor and molecular approaches to study the contributions of PSMB6 in DM resistance: the proteasome inhibitor MG-132 and bortezomib were used to suppress the proteasomal activity and siRNA was designed to block the function of PSMB6. The results revealed that both MG-132 and bortezomib increased the susceptibility in DM-resistant cells and resistance larvae. Moreover, PSMB6 knockdown decreased cellular viability under DM treatment. Taken together, our study indicated that PSMB6 is associated with DM resistance in mosquitoes and that proteasome inhibitors such as MG-132 or bortezomib are suitable for use as a DM synergist for vector control.

show abstract

“…However, because BD and IP genes represent sustained and transient drug-induced changes, respectively, their overlaps may still be irrelevant to drug resistance. Munkácsy et al proposed that IP genes should be excluded from BD genes [ 18 ]. However, some IP genes could be drug resistance genes, and it is difficult to determine which IP genes should be excluded.…”

Section: Introductionmentioning

confidence: 99%

Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post- chemotherapy tissues

Tong

Zheng

et al. 2015

Oncotarget

View full text Add to dashboard Cite

Until recently, few molecular signatures of drug resistance identified in drug-induced resistant cancer cell models can be translated into clinical practice. Here, we defined differentially expressed genes (DEGs) between pre-chemotherapy colorectal cancer (CRC) tissue samples of non-responders and responders for 5-fluorouracil and oxaliplatin-based therapy as clinically relevant drug resistance genes (CRG5-FU/L-OHP). Taking CRG5-FU/L-OHP as reference, we evaluated the clinical relevance of several types of genes derived from HCT116 CRC cells with resistance to 5-fluorouracil and oxaliplatin, respectively. The results revealed that DEGs between parental and resistant cells, when both were treated with the corresponding drug for a certain time, were significantly consistent with the CRG5-FU/L-OHP as well as the DEGs between the post-chemotherapy CRC specimens of responders and non-responders. This study suggests a novel strategy to extract clinically relevant drug resistance genes from both drug-induced resistant cell models and post-chemotherapy cancer tissue specimens.

show abstract

PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer

Cited by 41 publications

References 49 publications

cis -Regulatory Circuits Regulating NEK6 Kinase Overexpression in Transformed B Cells Are Super-Enhancer Independent

cis -Regulatory Circuits Regulating NEK6 Kinase Overexpression in Transformed B Cells Are Super-Enhancer Independent

Identification of Proteasome Subunit Beta Type 6 (PSMB6) Associated with Deltamethrin Resistance in Mosquitoes by Proteomic and Bioassay Analyses

Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post- chemotherapy tissues

Contact Info

Product

Resources

About